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Abstract
Background: Cardiovascular diseases are common cause of morbidity and mortality
in patients with systemic connective tissue diseases (SCTD) due to accelerated ath-
erosclerosis which couldn't be explained by traditional risk factors (CVDRF).
Hypothesis: We hypothesized that recently developed score predicting probability of
heart failure with preserved ejection fraction (H2FPEF), as well as a measure of right
ventricular-pulmonary vasculature coupling [tricuspid annular plane systolic excursion
(TAPSE)/pulmonary artery systolic pressure (PASP) ratio], are predictive of athero-
sclerosis in SCTD.
Methods: 203 patients (178 females) diagnosed with SCTD underwent standard and
stress-echocardiography (SE) with TAPSE/PASP and left ventricular (LV) diastolic fill-
ing pressure (E/e') measurements, carotid ultrasound and computed tomographic cor-
onary angiography. Patients who were SE positive for ischemia underwent coronary
angiography (34/203). The H2FPEF score was calculated according to age, body mass
index, presence of atrial fibrillation, ≥2 antihypertensives, E/e' and PASP.
Results: Mean LV ejection fraction was 66.3 ± 7.1%. Atherosclerosis was present in
150/203 patients according to: 1) intima-media thickness>0.9 mm; and 2) Agatstone
score > 300 or Syntax score ≥ 1. On binary logistic regression analysis, including
CVDRF prevalence, echocardiographic parameters and H2FPEF score, only H2FPEF
score remained significant for the prediction of atherosclerosis presence (χ2 = 19.3,
HR 2.6, CI 1.5-4.3, p < 0.001), and resting TAPSE/PASP for the prediction of a SE
positive for ischemia (χ2 = 10.4, HR 0.01, CI = 0.01-0.22, p = 0.004). On ROC analy-
sis, the optimal threshold value for identifying patients with atherosclerosis was a
H2FPEF score ≥2 (Sn 60.4%, Sp 69.4%, area 0.67, SE = 0.05, p < 0.001).
Conclusions: H2FPEF score and resting TAPSE/PASP demonstrated clinical value for
an atherosclerosis diagnosis in patients diagnosed with SCTD.
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1 | INTRODUCTION
Cardiovascular diseases (CVD) are the most common cause of morbidity
and mortality in patients with systemic connective tissue diseases
(SCTD) generally due to premature atherosclerosis.1 Current recommen-
dations suggest assessment of general CVD risk factors (CVDRFs) in
these patients, as part of risk prediction algorithms such as Systematic
Coronary Risk Evaluation (SCORE)2 and Framingham3 in order to calcu-
late a 10-year risk of CVD events. These traditional risk factors include
age, gender, blood pressure, smoking, diabetes mellitus, and hyperlipid-
emia and, according to calculated risk, preventive interventions are rec-
ommended.2,3 However, in SCTD, atherosclerosis cannot be explained
by traditional CVDRF alone.1,4 The play a secondary role, while disease-
specific factors can directly influence the cardiovascular system. Chronic
systemic inflammation and autoimmunity interfere in a number of meta-
bolic processes, generating a proatherogenic condition.1,4 In these
patients, CVD is also influenced by anti-inflammatory therapy.1,4 Thus,
the European League Against Rheumatism (EULAR) suggests screening,
identification of CVDRF, and CVD risk management in all patients with
SCTD.1 The EULAR task force has advocated the use of a 1.5 multiplica-
tion factor for these risk prediction models when certain rheumatoid
arthritis (RA) disease characteristics were present.1 However, appropriate
and validated SCTD-specific CVD risk prediction models are still lacking.1
On the other hand, there is an urgent need to identify cardiovascular
abnormalities early, before the development of irreversible damage.
It has been demonstrated that SCTDs are commonly associated
with heart failure preserved ejection fraction (HFpEF) and pulmonary
hypertension (PH),5,6 increasing the risk of death by almost twofold.7
The synergy amongst HFpEF, systemic inflammatory disorders and
atherosclerosis represents a vicious circle leading to very poor sur-
vival.5 As systemic inflammation precedes the onset of HFpEF and
atherosclerosis by years,8 it would be beneficial to conduct early risk
prediction in order to prevent future adverse events.
We hypothesized that the recently developed H2FPEF score, pro-
posed to predict the probability of HFpEF through a composite score
of six variables including age, body mass index (BMI), treatment with ≥2
antihypertensives, presence of atrial fibrillation, early diastolic filling
pressure (E/e' ratio) and pulmonary artery systolic pressure (PASP) mea-
sured by echocardiography,9 is also predictive of atherosclerosis in
patients diagnosed with SCTD. Moreover, we hypothesized that
parameters of right ventricular-pulmonary vasculature coupling (RV-PV
coupling) may also be predictive for atherosclerosis in this patient pop-
ulation. Thus, the purpose of the present investigation was to examine
the predictive value of H2FPEF score and tricuspid annular plane sys-
tolic excursion (TAPSE)/PASP ratio, as a measure of RV-PV coupling,
for atherosclerosis presence in patients diagnosed with SCTD.
2 | METHODS
2.1 | Study cohort
From January 2018 to November 2019, 203 patients with SCTD
(i.e., rheumatoid arthritis [RA], systemic lupus erythematosus [SLE],
systemic sclerosis [SSc], and Sjogren's syndrome [SS]) diagnosed
according to current criteria10-17 were enrolled in this prospective
observational study at the Clinical Center of Serbia. They were
screened for study enrollment at the time of referral for a clinically
indicated functional assessment. The study was approved by the local
Ethical Institutional Review Board and informed consent was obtained
from all subjects prior to enrollment. Clinical data from patients were
collected during a preliminary visit, including age, gender, height,
weight, BMI, and other CVDRFs (i.e., smoking status, hyperlipidemia,
obesity, hypertension, heredity for CVD, diabetes mellitus). CVD risk
was categorized as:(a) low; (b) intermediate; (c) high; and (d) very high
according to SCORE value, determined using European Society of
Cardiology (ESC) recommendations.2 Subjects afterwards underwent
a two dimensional (2-D) echocardiographic/Doppler evaluation, stress
echocardiography (SE), computed tomographic coronary angiography
(CTCA) and carotid ultrasound. Inclusion criteria were: (a) diagnosed
RA, SLE, SSc, SS; (b) no previously documented CVD; (c) adequate
echocardiographic windows; (d) left ventricular ejection fraction
(LVEF) ≥ 50%; and (e) ability to exercise. Patients with normal LVEF
and isolated tricuspid regurgitation due to a primary tricuspid valvular
lesion were not included in the present investigation.18 Care was
taken to identify the proper etiology of coexistent PH excluding idio-
pathic pulmonary arterial hypertension. Accordingly, we referred to
Opotowsky et al.19 who proposed and validated 5-point prediction
score based on the measurements of LV diastolic filling pressure
(E/e'), the antero-posterior diameter of the left atrium and notching
and/or shortened acceleration time of pulmonary flow. No subjects
had significant right ventricular outflow tract obstruction.
2.2 | Echocardiography
Echocardiographic imaging was performed using a Philips IE33 and a
5.2-MHz transducer (Philips Medical Systems, Andover, MA) by two
experienced cardiologists according to the current guidelines, at rest
and during SE.20,21 A 2-D and Doppler examination was performed
using a pre-specified echocardiographic protocol by views specifically
designed to optimize RV imaging.22 B–mode echocardiography was
performed to assess LVEF and left atrial volume (LAV) at rest. Early
(E) and late (A) LV diastolic filling velocity were assessed at rest and
during SE. Tissue Doppler imaging (TDI) was recorded at rest and dur-
ing SE at end-expiration in the apical four chamber view at a sweep
speed of 50 mm/s; the Doppler signal angle was less than 25%. Sam-
ple volume was positioned at 1 cm within the septal and lateral inser-
tion sites of the mitral leaflets. Digitally stored loops of TDI were used
for off-line calculations of myocardial velocities. Average values of LV
lateral and septal annular early diastolic filling velocities (e') were used
to calculate E/e'. The apical four-chamber view was used, and an M-
mode cursor was placed through the lateral tricuspid annulus in real
time to obtain TAPSE at rest and during SE. The brightness was
adjusted off-line to maximize the contrast between the M-mode sig-
nal arising from the tricuspid annulus and the background. TAPSE was
measured as the total displacement of the tricuspid annulus (millime-
ters) from end-diastole to end-systole, with values representing
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TAPSE being averaged over three to five beats.22 PASP was estimated
by Doppler echocardiography at rest and during SE from the systolic
RV to right atrial pressure gradient using the modified Bernoulli equa-
tion. Right atrial pressure (assessed jugular venous pressure) was
added to the calculated gradient to yield PASP. The TAPSE/PASP
ratio, a measure of RV-PV coupling,23 was calculated. Interobserver
variability, assessed in a sample size of 20% of total population, was
3.5%, 3.4%, and 2.8% for M-mode, 2-D echocardiography and TDI,
respectively.
2.3 | Stress echocardiography
All subjects performed SE on a treadmill using the Bruce protocol
according to established guidelines.24 Nitrates were stopped for 24 h,
beta blockers for 3 days and calcium antagonists for 48 h before SE. Tea,
coffee, cola-drinks, chocolate, and smoking were not allowed for 24 h
before the evaluation. Standard 12-lead electrocardiograms were
obtained after adequate skin preparation, at rest, each minute during
exercise, and for at least 5 min during the recovery phase, according to
established guidelines.24 Blood pressure was measured using a standard
cuff sphygmomanometer. Test termination criteria consisted of:
(a) symptoms (i.e., dyspnea and/or fatigue); (b) sustained ventricular tachy-
cardia (VT) and non-sustained VT that interfered with hemodynamic sta-
bility; (c) > 2 mm of horizontal or downsloping ST segment depression;
(d) a drop of systolic blood pressure > 20 mm Hg during progressive exer-
cise; (e) or reaching a submaximal heat rate (HR) calculated as 0.8
(220-age). Wall motion was recorded at the beginning of the SE and at
peak effort, and reported using a conventional 16-segment model.25 An
ischemic response (i.e., positive SE test) was defined as worsening LV wall
motion during exercise testing in comparison to the resting condition.25
2.4 | Coronary angiography
Coronary angiography was performed by the Judkins' technique.26
Stenosis was considered hemodynamically significant if there was
a ≥ 50% reduction in luminal diameter. In order to assess the severity
of CAD, the Syntax score was calculated.27 A Syntax score ≥ 1 was
used to define the presence of atherosclerosis.
2.5 | Computed tomographic coronary
angiography
Patients received nitroglycerin 0.8 mg sublingually and metoprolol
targeting a HR of ≤65 bpm before image acquisition. In order to calculate
the time interval between intravenous contrast (Visipaque 320, GE
Healthcare; Milwaukee, WI) infusion and image acquisition, a bolus track-
ing technique was used. A triphasic protocol was used for final image
acquisition (100% contrast, 40/60% contrast/saline, and 40 cc saline).
The infusion rate (5–6 cc/s) and contrast volume were individualized
according to the patient's body habitus and scan time. GE high-definition
CT (VCL Lightspeed 64 MD, GE) was used to acquire retrospective ECG-
gated data sets with the width 64 mm  0.625 mm slice collimation and
a gantry rotation of 350 ms (mA = 300–800, kV = 120). Pitch (0.16–
0.24) was individualized to the patient's HR. The CTCA data sets were
reconstructed with an increment of 0.4 mm using the cardiac phase with
the least cardiac motion. Images were interpreted by two radiologists
blinded to all clinical data. The Coronary calcium accumulation -
Agatstone score (AS) was determined according to established guide-
lines.28 An AS >300 was used to define the presence of atherosclerosis.
2.6 | Carotid ultrasound
Carotid ultrasound was performed by an experienced ultasonographer
who was blinded to the clinical data, using ACUSON Antares System
(Siemens AG, Munich, Germany) equipped with a 4–13 MHz linear
array transducer, according to established guidelines.29,30 Carotid
intima media thickness (CIMT) was measured after the subject was
placed in the supine position. The CIMT was defined as the distance
between edges of the lumen-intima and the media-adventitia echoes,
in a plaque-free section. CIMT was measured bilaterally, at the levels
of common carotid, carotid bifurcation and internal carotid artery.
Mean values were calculated for all segments. According to the results
of ARIC study, subclinical atherosclerosis was considered present if
CIMT was higher than 0.9 mm.31,32
2.7 | Blood analysis
C-reactive protein (CRP) was determined by particle enhanced
immunoturbimetric assay (Tina-quant CRP-latex; Roche Diagnostic
Corporation, Indianapolis, IN). The reference range for this assay is
less than 5 mg/L.
2.8 | Scoring
The H2FPEF score was calculated for each patient. The six variables
that constitute the H2FPEF score are: (a) BMI >30 kg/m
2 (2 points);
(b) use of ≥2 antihypertensive medications (1 point); (c) history of
atrial fibrillation (3 points); (d) PASP >35 mm Hg (1 point);
(e) age > 60 years (1 point); and (f) E/e' > 9 (1 point).9
2.9 | Statistical analysis
Continuous data are expressed as mean and standard deviation while
categorical data are expressed as percentages. In order to apply para-
metric statistics, analysis of distribution was performed by the
Kolmogorov–Smirnov test. The differences between the groups strati-
fied according to presence of atherosclerosis were assessed by the
Student's t test for independent samples. The Mann–Whitney test
was used for nonparametric variables. Correlations between variables
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were performed by Pearson's correlation test and the Spearman's rank
correlation test. Binary logistic regression analysis was performed to
identify the best model to predict the probability of atherosclerosis.
For the multivariate regression we used a forward conditional model
with stepwise entry and removal criteria set at 0.05 and 0.10, respec-
tively. Maximal iterations were set at 20. Hierarchical models were
defined considering statistical significance and clinical relevance of
independent variables, taking into consideration principal effects and
second level interactions in each model. Measures of interest for pre-
dictive ability were compared using area under the receiver operating
characteristic (ROC) curve. Two-by-two tables were built to estimate
senstitivity (Sn), specificity (Sp), predictive values and 95% confidence
intervals. Statistical tests were considered significant when a p-value
was <0.05 for all tests. The SPSS software package (SPSS version
27.0, SPSS Inc., Armonk, NY) was used for all analyses.
3 | RESULTS
For 203 patients with SCTD enrolled, the mean age was 57.7
± 11.2 years and 87.7% were female. The average time since diagno-
sis was 8.6 ± 7.9 years. Of the 203 subjects, 52 (25.6%) were
TABLE 1 Results of stress
echocardiography, coronary angiography,
computer tomographic coronary
angiography, and carotid ultrasound
Total Positive Negative
SE, n (%) 203/203 (100.0%) 34 (16.7%) 169 (83.3%)
Coronary angiography, n (%) 34/203 (16.7%) 18 (52.9%) 16 (47.1%)
CTCA, n (%) 203/203 (100%) 40 (19.7%) 163 (80.3%)
CIMT, n (%) 203/203 (100%) 139 (68.5%) 64 (31.5%)
Atherosclerosis, n (%) 203/203 (100%) 150 (73.9%) 53 (26.1%)
Note: Positive coronarography was considered Syntax score ≥ 1; positive CTCA AS >300, positive CIMT
was considered CIMT >0.9 mm and positive atherosclerosis AS >300 or IMT > 0.9 mm or Syntax
score ≥ 1.
Abbreviations: AS, Agatstone score; IMT, Intima-media thickness; SE, stress echocardigraphy.
TABLE 2 Echocardiographic characteristics of study patients
Mean ± SD
Positive
SE (n = 34)
Negative
SE (n = 169) p value
Documented
atherosclerosis (n = 149)
No documented
atherosclerosis (n = 54) p value
EF, % 62.3 ± 9.4 67.2 ± 6.4 <.001*** 66.1 ± 7.0 67.0 ± 7.7 .435
LVDd, mm 4.8 ± 0.7 4.8 ± 0.5 .972 4.8 ± 0.5 4.9 ± 0.5 .630
RVDd, mm 2.1 ± 0.4 2.0 ± 0.4 .033* 2.0 ± 0.4 1.9 ± 0.4 .033*
LAV, ml 35.8 ± 20.4 30.2 ± 11.0 .023* 32.8 ± 13.7 26.6 ± 10.4 .001**
LAV index, ml/m2 20.2 ± 11.0 16.6 ± 5.6 .050* 18.2 ± 7.2 14.5 ± 5.2 <.001***
VCI, mm 1.3 ± 0.4 1.3 ± 0.4 .906 1.3 ± 0.4 1.3 ± 0.3 .981
E/A rest 0.8 ± 0.3 0.9 ± 0.3 .290 0.9 ± 0.3 1.0 ± 0.4 .025*
E/A peak 1.0 ± 0.4 1.2 ± 1.6 .425 1.0 ± 0.4 1.7 ± 2.6 .003**
E/e' rest 10.4 ± 4.9 8.4 ± 2.6 .001** 9.1 ± 3.3 7.8 ± 2.6 .015**
E/e' peak 9.6 ± 4.4 8.8 ± 3.1 .229 9.2 ± 3.3 8.0 ± 3.2 .028*
PASP rest, mm Hg 39.5 ± 12.6 29.66 ± 6.4 <.001*** 32.1 ± 9.2 29.7 ± 7.7 .167
PASP peak, mmHg 46.1 ± 17.7 34.7 ± 9.1 <.001*** 38.2 ± 12.4 32.8 ± 9.9 .015*
TAPSE rest, mm 2.2 ± 0.4 2.3 ± 0.4 .025* 2.3 ± 0.4 2.3 ± 0.3 .603
TAPSE peak, mm 2.6 ± 0.4 2.8 ± 0.4 .005** 2.8 ± 0.4 2.8 ± 0.4 .867
TAPSE/PASP rest,
mm/mm Hg
0.59 ± 0.20 0.83 ± 0.24 <.001*** 0.76 ± 0.22 0.88 ± 0.31 .013*
TAPSE/PASP peak,
mm/mm Hg
0.67 ± 0.38 0.87 ± 0.27 .002** 0.79 ± 0.30 0.94 ± 0.29 .011*
Note: Documented atherosclerosis considered Agatstone score > 300 or IMT > 0.9 mm or Syntax score ≥ 1.
Abbreviations: A, late diastolic filling velocity of the left ventricle; e', average of septal and lateral early left ventricular diastolic filling velocity measured by
tissue Doppler; E, early diastolic filling velocity of the left ventricle; EF, ejection fraction; LAV, left atrial volume; LVDd, left ventricular end-diastolic
diameter; PASP, systolic pressure in pulmonary artery; RVDd, right ventricular end-diastolic diameter; TAPSE, tricuspid annular plain systolic excursion;
VCI, diameter of vena cava inferior.
*P < 0.05, **P < 0.01 and ***P < 0.001.
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diagnosed with RA, 51 (25.1%) with SLE, 50 (24.6%) with SSc and
50 (24.6%) with SS. Twenty eight of the subjects were only receiving
symptomatic therapy (13.8%), 65 (32.0%) were receiving mon-
otherapy (i.e. immunosuppressive drugs or biological therapy) and
110 (54.2%) were receiving combined specific therapy. The clinical
data and the prevalence of CVDRF are given in Table S1.
All patients underwent SE testing; 34/203 (16.7%) tests were
described as positive in terms of the presence of myocardial ischemia.
All subjects with a positive SE test underwent catheterization and, of
those catheterized,18/34 (52.9%) had significant lesions in the coro-
nary arteries detected (Syntax score ≥ 1). Average Syntax score of all
catheterized subjects was 8.3 ± 14.6. Of 18 patients with a Syntax
score ≥ 1, five patients underwent a further revascularization proce-
dure (two for percutaneous coronary intervention and three for coro-
nary artery by pass graft).
CTCA and CIMT measurements were performed in all subjects;
40/203 (19.7%) had AS >300 and 139/203 (68.5%) had CIMT
>0.9 mm. Average AS was 286.3 ± 696.3 and average CIMT was
1.2 ± 0.6 mm.
Subjects who demonstrated a AS >300, CIMT >0.9 mm or Syntax
score ≥ 1 were arbitrarily considered to have documented atheroscle-
rosis, as given in Table 1.
Echocardiographic data of patients with and without a positive SE
test, as well as the presence or absence of atherosclerosis, are given
in Table 2. RVDd, LAV, LAV index, resting E/e' and peak PASP were
higher, while TAPSE/PASP at rest and peak were lower in subjects
with positive SE and documented atherosclerosis. Patients with a pos-
itive SE test also had a lower LVEF and resting and peak TAPSE,
whereas resting PASP was higher than in patients with a negative SE
test. Patients with documented atherosclerosis had a lower resting
and peak E/A and higher peak E/e' compared to patients with no
documented atherosclerosis.
All patients had a LVEF ≥50%, except three patients that had a
LVEF of 45%, which were excluded from further analysis. Mean
H2FPEF score for patients with a LVEF ≥50% was 1.8 ± 1.4. H2FPEF
score significantly correlated with the presence of atherosclerosis and
SE positivity (r = 0.3, 0.2; p < .001, p = .005, respectively). H2FPEF
score significantly correlated with TAPSE/PASP at rest and peak
(r = 0.3,  0.2; p = .001, .013, respectively).
On binary logistic regression analysis, CVDRF category, number
of CVDRFs, VCI diameter, CRP and duration of illness were not signif-
icant predictors of atherosclerosis presence or a positive SE test. Sig-
nificant predictors of both atherosclerosis presence and a positive SE
test were RVDd, E/e' rest, LAV, LAV index, TAPSE/PASP at rest and
peak, and H2FPEF score as given in Table 3 (A,B). LVEF was not a sig-
nificant predictor of atherosclerosis presence, but significantly
predicted a positive SE test. Peak E/e' significantly predicted athero-
sclerosis presence but did not have predictive value for a positive SE
test. In a multivariate model, including all significant univariate predic-
tors, only H2FPEF score remained in the regression for the prediction
of atherosclerosis presence (χ2 = 19.3, HR 2.6, CI 1.5–4.3, p < .001).
When H2FPEF score was removed from the analysis, the only predic-
tor that remained in the equation was peak TAPSE/PASP (χ2 = 4.1,
HR 0.2, CI 0.1–1.0, p = .049). In the multivariate model, the only pre-
dictor that remained in the regression for the prediction of SE positiv-
ity was resting TAPSE/PASP (χ2 = 10.4, HR 0.01, CI 0.01–
0.22, p = .004).
In order to detect parameters to distinguish between those
patients with and without atherosclerosis, ROC analysis was addition-
ally used. The best predictive ability was shown for the H2FPEF score
(area under ROC curve 0.67, SE = 0.05, p < .001). The optimal thresh-
old value for identifying patients with atherosclerosis was a H2FPEF
score ≥ 2, which produced a Sn and Sp of 60.4% and 69.4%, respec-
tively, as shown in Figure 1. Predictive value was also shown for peak
TAPSE/PASP (area under ROC curve 0.35, SE = 0.05, p = .004), as
shown at Figure S1.
On ROC analysis, H2FPEF score was also shown to have a predic-
tive value for identifying patients with positive and negative SE test
TABLE 3 Univariate and multivariate binary logistic regression
analysis for key clinical and echocardiographic variables in the
prediction of (A) atherosclerosis presence and (B) positivity of SE
(A) χ2 Hazard ratio 95% CI p value
Univariate analysis
RVDd 4.2 2.5 1.0–5.9 .046*
LAV index 14.2 1.1 1.0–1.2 .001**
LAV 9.9 1.0 1.0–1.1 .035*
E/e'a rest 7.0 1.2 1.0–1.3 .015*
E/e'a peak 5.3 1.1 1.0–1.3 .031*
TAPSE/PASP rest 5.9 0.2 0.1–0.7 .017*
TAPSE/PASP peak 6.0 0.2 0.1–0.8 .016*
H2FPEF score 10.7 1.5 1.2–2.0 .002**
Multivariate analysis
H2FPEF score 19.3 2.6 1.5–4.3 <.001***
(B) χ2 Hazard ratio 95% CI p value
Univariate analysis
EF 12.4 0.9 0.9–1.0 .001**
RVDd 4.4 2.7 1.1–6.9 .036*
LAV index 6.6 1.1 1.0–1.1 .010*
LAV 4.6 1.0 1.0–1.1 .030*
E/e'a rest 9.9 1.2 1.1–1.3 .003**
TAPSE/PASP rest 27.6 0.01 0.01–0.03 <.001***
TAPSE/PASP peak 12.6 0.04 0.01–0.29 .002**
H2FPEF score 6.1 1.4 1.1–1.9 .013*
Multivariate analysis
TAPSE/PASP rest 10.4 0.01 0.01–0.22 .004**
Note: Documented atherosclerosis considered Agatstone score > 300 or
IMT > 0.9 mm or Syntax score ≥ 1.
Abbreviations: E, early diastolic filling velocity of the left ventricle; e'a,
average of septal and lateral early left ventricular diastolic filling velocity
measured by tissue Doppler; EF, ejection fraction; H2FPEF score, heart
failure preserved ejection fraction score; LAV, left atrial volume; PASP,
systolic pressure in pulmonary artery; RVDd, right ventricular end-diastolic
diameter; TAPSE, tricuspid annular plain systolic excursion.
*P < 0.05, **P < 0.01 and ***P < 0.001.
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(area under ROC curve 0.67, SE = 0.05, p = .006). The optimal thresh-
old value for identifying patients with a positive SE test was a H2FPEF
score ≥ 2, which produced a Sn and Sp of 76.0% and 48.7%, respec-
tively, as shown in Figure 2. A predictive value in distinguishing
between a positive and negative SE test was also shown for resting
TAPSE/PASP (area under ROC curve 0.21, SE = 0.05, p < .001), as
shown at Figure S2.
4 | DISCUSSION
The present findings demonstrate that more than two thirds of
patients with SCTD had occult atherosclerosis. Patients with athero-
sclerosis demonstrate a worsened echocardiographic phenotype as
indicated by a larger RV and LA, higher LV diastolic filling pressures at
rest and during exercise, as well as a lower resting and peak TAPSE/
PASP, suggesting worse RV-PV coupling. The recently developed
H2FPEF score, a powerful tool in predicting HFpEF presence,
9 out-
performed all other measures assessed in the present study, including
the ESC CVD risk categorization, in the prediction of atherosclerosis
presence. A high predictive value for atherosclerosis presence and
development of myocardial ischemia in patients diagnosed with SCTD
was also demonstrated for rest and peak TAPSE/PASP, and they both
significantly correlated with H2FPEF score.
Accumulating evidence points to the existence of increased CVD
risk in patients diagnosed with SCTD in comparison to the general
population, particularly in patients with RA, whose risk is comparable
with diabetes mellitus.32-34 Studies show that the risk of myocardial
infarction is approximately 70% higher in these patients than in gen-
eral population.35 Early recognition of CVD risk in SCTD patients is of
a great clinical importance, as that would prevent future adverse
events and poor survival. There is a need to find an easy method, fea-
sible not only for experts in cardiology and internal medicine, but
every other physician involved in care of patients diagnosed with
SCTD. In addition to standard CVDRFs which are emphasized in
SCTD, such as physical inactivity due to functional disability, common
concomitant hypothyroidism, diabetes mellitus, hyperlipidemia,
chronic kidney disease and hypertension, there are novel risk factors
playing a role in this condition, such as inflammation and applied ther-
apy.1 Drugs with powerful suppression of inflammation may slow
down progression of atherosclerosis.1 There is accumulating evidence
that decreasing the inflammatory burden, by biologic therapy, RA
patients translates into a lower CVD risk.1 Besides RA, no other SCTD
is currently incorporated into any widely accepted CVD risk calcula-
tors.2 This is not appropriate approach, as accelerated atherosclerosis
and heart failure coexist in all distinct phenotypes of SCTD.5,32,34,36
The mechanisms that contribute to accelerated atherosclerosis are still
incompletely understood. Chronic systemic inflammation and autoim-
munity interfere in a number of metabolic processes, influencing liver
function, skeletal muscles, and fat tissue, generated a proatherogenic
condition.1,4 The proinflammatory cytokines, such as tumor necrosis
factor (TNF)-α and interleukin (IL)-6, lead to endothelial dysfunction
and activation, primarily in patients with RA.1 Enhanced expression of
F IGURE 1 Receiver operating characteristic (ROC) curve
demonstrating predictive ability of H2FPEF score ≥ 2 for identifying
patients with atherosclerosis presence
F IGURE 2 Receiver operating characteristic (ROC) curve
demonstrating predictive ability of H2FPEF score ≥ 2 for identifying
patients with positive SE test
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adhesion molecules (such as vascular cell adhesion protein 1, or
VCAM-1) on the endothelial and smooth muscle cell surfaces is asso-
ciated with cardiovascular disorders in RA and SLE.4 In SLE patients
CVD are generally independent of traditional risk factors and SLE
itself has been shown to be a substantial risk factor for the develop-
ment of atherosclerosis.4,35 In addition to the role of inflammation,
patients with SLE have antinuclear antibodies which might have a
pathophysiological role.4 The underlying mechanisms for atheroscle-
rosis in patients with SSc involve endothelial injury and reduced oxy-
gen transport to tissues. SSc (both limited and diffuse disease) is also
associated with increased stiffness of the vasculature.7 Although RA
exhibited the highest CVD risk, the one is only slightly lower in SSc,
SLE, and SS.1,33,36 This observation was encouraging to examine all
these SCTD in the current study. Although highly recommended to
determine,1,2 SCORE CVD risk evaluation in patients with SCTD
underestimates real CVD risk.1 Even with a deeper diagnostic
approach suggested by guidelines, including screening for asymptom-
atic atherosclerotic plaques through carotid ultrasound, CVD risk esti-
mation is still based on expert opinion.1,2 Previous evidence indicates
SCTD leads to myocardial inflammation, abnormalities of coronary
microcirculation, diastolic dysfunction, LA enlargement, and finally
HFpEF.7 Interestingly, women have greater risk and suffer greater car-
diac consequences from these systemic inflammatory and metabolic
disorders.5 Coronary artery calcifications, a marker of coronary ath-
erosclerosis, are shown to stratify risk of HFpEF beyond traditional
risk factors in women.29 Accordingly, a new marker was recently iden-
tified, an inflammatory-metabolic phenotype of HFpEF, characterized
by biomarkers of inflammation, microvascular endothelial dysfunction,
normal-to-mildly increased left ventricular volumes and systolic blood
pressures, and altered activity of adipocyte-associated inflammatory
mediators.5 This HFpEF phenotype may express independent of large
vessel coronary artery disease.5 The proposed underlying pathophysi-
ology for this condition is an inflammatory response to an ectopic
accumulation of dysfunctional lipids, in the epicardium or small coro-
nary vessels, leading to fibrosis of the adjacent myocardium, ventricu-
lar and atrial, with consequent impairment of diastolic function and
atrial fibrillation.5,30,31 This sequence could explain the link between
accelerated atherosclerosis in SCTD and HFpEF development.31 In
support, our study demonstrated larger LA, and higher LV diastolic fill-
ing pressures at rest and during effort in SCTD subjects with positive
SE and documented atherosclerosis, but also the impact on RV func-
tion and worsening RV-PV coupling, which is an increasingly impor-
tant feature in HFpEF.32 Previous studies have demonstrated that
right heart function is a crucial determinant of outcome in HF patients
regardless of LV function or predominance of systolic or diastolic
HF.33 In atherosclerotic patients, abnormalities in PASP and PVR are
observed with a direct link to incident HFpEF and it is proposed that
impairments in PV function may precede clinical HFpEF.34 Accord-
ingly, the link between TAPSE/PASP as a measure of RV-PV coupling
and RV function was shown to provide a comprehensive tool for risk
stratification in HFpEF.32 In our study, the TAPSE/PASP response
demonstrated a high predictive value for atherosclerosis presence and
positive SE test, outperforming other LA and LV parameters,
suggesting the importance of RV and pulmonary circulatory dysfunc-
tion in atherosclerotic patients with SCTD. The significant correlation
of TAPSE/PASP with the H2FPEF supports the link of RV-PV
uncoupling and HFpEF, which is already very well known.35
Nonetheless, a H2FPEF score was superior to TAPSE/PASP both
at rest and peak exercise in the prediction of atherosclerosis presence,
supporting its' comprehensive nature in assessing clinical status. Con-
sidering the potential presence of both HFpEF and atherosclerosis in
SCTD patients, the strong predictive value of the H2FPEF score is not
surprising, as all components of the score are in a way a reflection of
underlaying pathophysiology. Some previous studies have demon-
strated that a high H2FPEF score may be associated with a high SYN-
TAX score and may be used to estimate the extent and complexity of
coronary artery disease.36 Simplicity of the determination and calcula-
tion of the H2FPEF score is of a particular value from a clinical per-
spective, which may help planning further diagnostic procedures in
the evaluation of SCTD patients with suspected atherosclerosis.
5 | LIMITATIONS
A limitation of this study is the lack of invasive hemodynamic evalua-
tion for HFpEF presence. Sub analyses on age and gender were not
performed due to the limited numbers in specific subsets of patients,
which should be addressed in future studies. Moreover, to define the
presence of atherosclerosis, the cut off values were arbitrarily chosen.
While CIMT >0.9 mm is commonly used and easily understood by most
clinicians37, the impact of age and sex cannot be neglected.38 Further-
more, CIMT measurements were usually performed at the common
carotid artery, however previous studies differed according to measure-
ment side (left side versus right side), measurement wall (far wall versus
near wall) and method of combination of single measurements (mean
versus mean-maximum).39,40 The use of different ultrasound machines
with varying transducer frequencies may also be impactful.39,40 Syntax
score ≥ 1 is another cut off determinant that could be understood as
too low, however, the intention was to identify any presence of athero-
sclerosis, regardless of its significance. The cut off for AS >300 was
chosen as it was shown previously to be associated to markedly
increased CVD risk, however that risk was observed in patients with AS
>100 as well.41 Another limitation of the current study is low H2FPEF
score observed in study population. Future studies with more severe
patients and higher score are warranted.
6 | CONCLUSIONS
The H2PHEF score has strong predictive value for atherosclerosis
presence in patients diagnosed with SCTD. The same was shown for
TAPSE/PASP measured at rest and during peak exercise, novel unfa-
vorable markers of RV-PV uncoupling and RV dysfunction, which cor-
relate with the H2PHEF score. Present findings indicate the need to
systematically calculate H2PHEF score in patients with SCTD in order
to help reveal occult atherosclerosis.
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